The US Food and Drug Administration has approved Moderna's flu vaccine mFlusiva for adults aged 50 and older. It is the first seasonal flu vaccine built on mRNA technology to reach the US market. The approval arrives in time for the 2026-27 flu season. (Engadget, New York Times)

mRNA technology is the same approach Moderna used for its COVID-19 vaccine. Instead of injecting a weakened or dead virus to trigger an immune response, an mRNA vaccine delivers a set of genetic instructions. Your cells read those instructions and produce a harmless piece of the virus, which teaches your immune system to recognize and fight the real thing. The main advantage is speed: mRNA vaccines can be designed and manufactured faster than traditional flu vaccines, which are grown in chicken eggs or cell cultures over several months.

The approval process was bumpy. The FDA initially refused to even review Moderna's application. The agency argued that Moderna had compared its vaccine against a standard flu shot when it should have used a stronger, higher-dose vaccine designed for older adults. Less than a week later, the FDA reversed course and agreed to review the application. (Engadget, CIDRAP)

The approval covers adults 50 and older but uses two different pathways depending on age. For adults aged 50 to 64, the FDA granted standard approval based on a large clinical trial that enrolled 40,805 people across 11 countries. For adults 65 and older, the FDA used a faster pathway called accelerated approval. This lets a vaccine reach the market based on promising early evidence, with the requirement that the company continues studying the vaccine to confirm it works. (Engadget, Reuters)

An FDA advisory committee voted unanimously in favor of the vaccine's benefits outweighing its risks before the approval was finalized. (Moderna)

mFlusiva protects against the four most common flu strains, matching the coverage of standard flu vaccines. In Moderna's trial, the vaccine performed better than standard flu shots at preventing flu-like illness in adults 50 and older. FDA briefing documents reported 47.9% efficacy against a study endpoint, which the agency described as clinically meaningful. (Engadget, FDA, PubMed)

The vaccine has been tested in humans since 2021. Moderna has also started a two-season trial to gather more data on how well the vaccine works across back-to-back flu seasons. (Engadget, Moderna Investor Relations)

FDA documents stated that approving an mRNA flu vaccine would help prepare the country for a future flu pandemic. The idea is that once a vaccine platform is approved and validated, manufacturers can use it to quickly produce a new vaccine targeted at whatever flu strain emerges in an outbreak. (FDA)

The broader context here goes beyond a single vaccine. Moderna had also submitted an application for a combined flu and COVID-19 vaccine in early 2025 but withdrew it in May 2025. The mFlusiva approval gives Moderna a regulatory foothold for its non-COVID mRNA vaccines and establishes a platform that future combination vaccines could build on. (Moderna Investor Relations, January 2025, Moderna Investor Relations, May 2025)

The FDA's initial objection about the comparator vaccine is worth noting. The agency felt Moderna should have tested its vaccine against a stronger flu shot designed for older adults, not a standard one. That the FDA ultimately accepted the data and approved the vaccine suggests the results were strong enough to overcome that concern. But the split approach, standard approval for 50-64 and accelerated approval for 65-plus, shows the agency still had less certainty about how well the vaccine works in the oldest group.

The pandemic-preparedness argument in the FDA's own documents may be the most important part of this story for the long term. Having a licensed mRNA flu vaccine means that if a dangerous new flu strain emerges, manufacturers and regulators already have a tested and approved platform to build on, saving valuable time. Whether that preparedness pays off depends on manufacturing capacity, public willingness to get the vaccine, and more data on how well it performs over multiple flu seasons. Those are all open questions as mFlusiva heads into its first commercial flu season.